8-[4-(1H-indol-3-yl)-piperidin-1-ylmethyl]-2,9-dihydro-1,2,7,9-tetraaza-phenalen-3-one | 1140965-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 8-[4-(1H-indol-3-yl)-piperidin-1-ylmethyl]-2,9-dihydro-1,2,7,9-tetraaza-phenalen-3-one
• 英文别名: 11-[[4-(1H-indol-3-yl)piperidin-1-yl]methyl]-2,3,10,12-tetrazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8,11-pentaen-4-one
• CAS: 1140965-04-3
• 化学式: C₂₃H₂₂N₆O
• 分子量: 398.467
• InChiKey: VMVNHGAMUZIEBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  85.9
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Xu Weizheng

  公开号：US20090098084A1

  公开（公告）日：2009-04-16

  The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.

  本发明涉及四氮杂苯并-3-酮化合物，其抑制聚(ADP-核糖)聚合酶(PARP)并在化疗敏感性中有用。周围神经病是许多传统和新型化疗药物的常见副作用。本发明进一步提供可靠预防或治愈化疗诱导的神经病的方法。本发明还涉及使用所披露的PARP抑制剂化合物来增强化疗药物如替莫唑胺的疗效。本发明还涉及使用所披露的PARP抑制剂化合物来使肿瘤细胞对电离辐射产生放射敏化作用。本发明还涉及使用所披露的PARP抑制剂化合物治疗DNA修复缺陷的癌症。
• PARP inhibitor compounds, compositions and methods of use
  申请人：Eisai Inc.

  公开号：EP2842956A1

  公开（公告）日：2015-03-04

  The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy- induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.

  本发明涉及抑制聚（ADP-核糖）聚合酶（PARP）的四氮杂萘-3-酮化合物，可用于癌症治疗的化疗增敏。诱发周围神经病变是许多传统和新型化疗药物的常见副作用。本发明进一步提供了可靠地预防或治疗化疗诱导的神经病变的方法。本发明还涉及所公开的 PARP 抑制剂化合物在提高替莫唑胺等化疗药物疗效方面的用途。本发明还涉及使用所公开的 PARP 抑制剂化合物使肿瘤细胞对电离辐射辐射敏感。本发明还涉及使用所公开的 PARP 抑制剂化合物治疗有 DNA 修复缺陷的癌症。
• US8236802B2
  申请人：——

  公开号：US8236802B2

  公开（公告）日：2012-08-07
• US8894989B2
  申请人：——

  公开号：US8894989B2

  公开（公告）日：2014-11-25
• [EN] PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS INHIBITEURS DE LA PARP, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：MGI GP INC

  公开号：WO2009046205A1

  公开（公告）日：2009-04-09

  The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy- induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.